Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Johnson & Johnson

NYSE: JNJ · Life Sciences · 2 alerts · CIK 200406

Share price
$282.55Close, Nov 16
Market cap
$680B
Shares outstanding
2.41BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Johnson & Johnson filings on SEC EDGAR ↗

4:20 PM ET 10-Q
Financial Results

Johnson & Johnson Q3 2026 Results: Net Income $210M, Down 95.9% YoY

Johnson & Johnson reported 2,407,310,266 shares of common stock outstanding as of October 15, 2026. The filing outlines the company's financial results for the fiscal third quarter and nine months ended September 27, 2026, while highlighting strategic risks including the planned separation of its Orthopaedics business.

Key figure
Net income $210M · -95.9% YoY
8:13 AM ET 8-K
Financial Results

Johnson & Johnson Financial Results

Johnson & Johnson reported Q3 2026 sales growth of 5.9% to $25.4 billion, driven by strong performance in its Innovative Medicine and MedTech segments. The company raised its full-year 2026 guidance for both sales and adjusted EPS, despite a GAAP earnings impact from a one-time special charge related to talc litigation and recent M&A activity.

Term
Q3 2026

“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio.”

Joaquin Duato, Chairman and Chief Executive Officer

“This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”

Joaquin Duato, Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.